by Marisa Wexler, MS | Nov 17, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved ziftomenib to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 gene mutation who have no satisfactory alternative treatment options. The once-daily oral therapy,...
by MM360 Staff | Nov 17, 2025 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Nov 15, 2025 | Publications
Leuk Lymphoma. 2025 Oct;66(10):1767-1777. doi: 10.1080/10428194.2025.2513676. Epub 2025 Jun 3. ABSTRACT Eligibility for autologous transplantation is a key factor for tailoring treatment decisions in patients with newly-diagnosed multiple myeloma. For non-eligible...
by Marisa Wexler, MS | Nov 14, 2025 | Myeloma News
Capsovision is requesting that the U.S. Food and Drug Administration (FDA) expedite the development of its CapsoCam UGI capsule endoscopy system as a potential tool for detecting early-stage pancreatic cancer. The CapsoCam system is similar to a large pill containing...
by MM360 Staff | Nov 14, 2025 | Uncategorized
Capsovision is requesting that the U.S. Food and Drug Administration (FDA) expedite the development of its CapsoCam UGI capsule endoscopy system as a potential tool for detecting early-stage pancreatic cancer. The CapsoCam system is similar to a large pill containing...
